Elastomeric Infusion System Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Variable Rate Elastomeric Pumps, Continuous Rate Elastomeric Pumps), By Treatment (Pain management, Antibiotic/ Antiviral, Chemotherapy, Others), By End users (Ambulatory Surgical Centres, Clinics, Home Care Settings, Hospitals and Others), and Region Forecast 2020-2031

Elastomeric Infusion System Market size was valued at US$ 680 million in 2024 and is projected to reach US$ 1.30 billion by 2031, expanding at a 7.0% CAGR from 2025 2031. Moreover, the U.S. Elastomeric Infusion System Market is expected to grow significantly, reaching an estimated US$ 520 million by 2031. The market is becoming more and more strategically relevant as healthcare delivery transitions to ambulatory care and patient-centric solutions. This battery less, compact infusion sets are used extensively for regulated drug delivery in oncology, pain therapy, and antibiotic treatment offering reliability without the burden of monitoring. The market is finding support in increasing demand for home infusion therapy and post-operative pain management, particularly from advanced economies possessing better homecare infrastructure. Increasing incidence of chronic illnesses, coupled with initiatives to reduce hospital readmission, are driving elastomeric systems into being an inevitable component of modern treatment regimens, thereby finding support for growth for the market across the globe.

Innovation and compliance are defining the competitive landscape of the market. Material science innovations, in the guise of medical-grade elastomers, are improving device precision and patient safety. Concurrently, reimbursement systems favouring low-cost outpatient procedures and policies encouraging cost-efficient outpatient procedures are driving healthcare systems adoption. Market leaders are considering tailored designs and adding antimicrobial functionality to minimize infection risk. In addition, developing markets are also witnessing swift market penetration driven by de-centralization of healthcare facilities and growing procedural volumes. With more emphasis being placed on mobility, efficiency, and patient comfort, the market is likely to post significant growth.

Facts & Figures

• A higher aging population with chronic conditions increases demand for long-term treatment products through elastomeric pumps.
• Osteomyelitis affects approximately 50,000 individuals annually in the U.S., with rising prevalence in children, older adults, and men (October 2024 released study).

Key Developments

• From January 2025, ON-Q* Elastomeric Infusion Pump and ambIT* Disposable Electronic Infusion Pump will be paid separately under NOPAIN Act.
• In Jan 2024, A new elastomeric pump technique was launched by the East and North Hertfordshire NHS Trust that would allow nurses to administer antibiotics to clients more quickly using one daily visit and cut visits by nurses.
• In August 2023, the U.S. FDA cleared ICU Medical Inc.'s Plum Duo infusion pump with LifeShield infusion safety software to improve safety and usability.
• In July 2023, BD (Becton, Dickinson and Company), a worldwide medical technology leader, released the news that the new BD Alaris™ Infusion System has been granted 510(k) clearance by the United States Food and Drug Administration (FDA), allowing remediation and resumption of full commercial operations for the most sophisticated infusion system in the United States.

Elastomeric Infusion System Market Segmentation

Based on the product type

• Variable rate Elastomeric Pumps
• Continuous Rate Elastomeric Pumps

Continuous rate elastomeric pumps are the most prevalent type of the market due to their simplicity in operation, dependability, and unintermittent drug delivery mechanism. They are used worldwide in post-operative pain management, chemotherapy, and antibiotic therapy, where unintermittent and accurate infusion is unavoidable. Their lack of dependency on battery or electronic programming makes them worthy of hospital and home administrations, especially in low-resource settings. Besides, the clinicians prefer them due to their ease of maintenance, low chance of error, and patient-centeredness. With the entire globe's health systems becoming outpatient and home-based treatment models, constant rate system demand grows nonstop, making them market dominance leaders.

Based on the treatment

• Pain management
• Antibiotic/ Antiviral
• Chemotherapy
• Others

Pain management is the most prominent treatment segment of the market due to rising use of non-electric, continuous analgesic administration in homecare and inpatient environments. Post-surgical recovery procedures and Orthopedic treatments more and more depend on the use of elastomeric pumps for prolonged, targeted pain relief to minimize reliance on systemic opioids. The pumps provide improved mobility and safety, particularly in outpatient cases, where the emphasis is placed on early discharge. The possibility of providing individualized flow rates and flow durations as per clinical needs makes them the perfect choice for multimodal pain control. With greater emphasis being laid on patient comfort and shorter hospital stays, pain control continues to dominate market needs.

Based on the end user

• Ambulatory Surgical Centres
• Clinics
• Home Care Settings
• Hospitals
• Others

Hospitals are the most frequent end-user segment in the market due to their heavy patient loads, clinical acuity, and reliance on regulated drug delivery for both post-operative and acute care. Hospitals would be likely to need continuous, electric-free infusion systems for the delivery of antibiotics, painkillers, and chemotherapy drugs, especially for recovery units and isolation areas. Elastomeric pumps present a low-maintenance, safe, and continuous infusion solution, minimizing dependency on electric infusion devices and nursing visits. Their well-documented history in infection control protocols, and with positive reimbursement incentives in the institutional environment, positions hospitals as the first introduction platform for product use, facilitating consistent segmental expansion globally.